Lehigh Valley Health Network is joining Strata Oncology’s Precision Oncology Network, according to an August 2 news release.
The partnership will allow Lehigh Valley Health Network’s advanced cancer patients to receive molecular profiling of tumors and participate in clinical medical trials at no cost.
Lehigh Valley Health Network or LVHN is one of five health systems joining the Strata Precision Oncology Network or “the Network.” The others are Baptist Health in Kentucky, MultiCare Health System in Washington, Prisma Health in South Carolina and Marshfield Clinic in Wisconsin.
Strata, which launched the Network in 2017, is a precision oncology company headquartered in Ann Arbor, Michigan.
The Strata Trial, which began July 12 at Lehigh Valley Hospital-Cedar Crest and Lehigh Valley Hospital-Muhlenberg, provides routine tumor molecular profiling and will now be available at more than 100 hospitals across the Strata Precision Oncology Network, covering 140,000 newly diagnosed cancer patients annually.
Strata Oncology’s portfolio of pharma-sponsored clinical trials will be available to eligible patients at the Lehigh Valley Cancer Institute.
“The addition of these health systems to the Network expands our reach to 40,000 patients each year with newly diagnosed advanced disease,” said Dan Rhodes, CEO of Strata Oncology.
“Together we are working to solve the unique hurdles integrated health systems face in implementing a large-scale precision oncology program, including routine tumor profiling, rapid interpretation of test results, and local access to precision therapy trials.”
Strata Oncology launched the Network with the aim of providing advanced cancer patients with access to comprehensive tumor molecular profiling and precision medicine clinical trials.
“Lehigh Valley Health Network has a longstanding commitment to deliver high-level care to cancer patients across eastern Pennsylvania,” said Suresh Nair, physician-in-chief of the Lehigh Valley Cancer Institute. “This partnership positions Lehigh Valley Cancer Institute on the cutting-edge of providing patients access to the latest technology and clinical research in precision oncology.”
Nair said LVHN will be able to offer Strata testing at no cost, and that the test features an expanded gene panel, from 90 to 500 cancer genes, and includes analytical validation of 36 emerging gene expression biomarkers, compared to commercial gene sequencing tests that can cost patients as much as $5,000 in copays.
Nair said that as many as 1,000 LVHN patients may benefit from as much as $5 million of free testing yearly for three years of current funding.
Lehigh Valley Health Network includes eight hospital campuses, three in Allentown, one in Bethlehem, one in East Stroudsburg, one in Hazleton and two in Pottsville, 26 health centers caring for communities in seven counties; numerous primary and specialty care physician practices and 19 ExpressCARE locations throughout the region.